share_log

中國中藥:截至二零二三年十二月三十一日止月份之股份發行人的證券變動月報表

TRAD CHI MED: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2023

香港交易所 ·  Jan 3 03:37
Summary by Moomoo AI
中國中藥控股有限公司於2024年1月3日向香港交易及結算所有限公司提交了截至2023年12月31日的證券變動月報表。報表顯示,該公司在報告月份內沒有發生任何股份變動,包括普通股、股份期權、權證、可換股票據及其他相關協議或安排。此外,公司確認所有發行的證券均已獲得董事會批准,並符合香港聯合交易所有限公司證券上市規則的所有要求。報表由聯席公司秘書趙東吉呈交。
中國中藥控股有限公司於2024年1月3日向香港交易及結算所有限公司提交了截至2023年12月31日的證券變動月報表。報表顯示,該公司在報告月份內沒有發生任何股份變動,包括普通股、股份期權、權證、可換股票據及其他相關協議或安排。此外,公司確認所有發行的證券均已獲得董事會批准,並符合香港聯合交易所有限公司證券上市規則的所有要求。報表由聯席公司秘書趙東吉呈交。
China Pharmaceutical Holdings Limited filed with Hong Kong Trading and Settlement Limited on 3 January 2024 with Hong Kong Trading and Settlement Holdings Limited its Monthly Securities Change Report for the year ended 31 December 2023. THE REPORT SHOWS THAT THE COMPANY DID NOT HAVE ANY CHANGES IN SHARES DURING THE REPORTING MONTH, INCLUDING ORDINARY SHARES, STOCK OPTIONS, WARRANTS, CONVERTIBLE STOCK NOTES AND OTHER RELATED AGREEMENTS OR ARRANGEMENTS. In addition, the Company confirms that all securities issued have been approved by the Board of Directors and comply with all the requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited. The report was presented by the Joint Company Secretary Zhao Dongji.
China Pharmaceutical Holdings Limited filed with Hong Kong Trading and Settlement Limited on 3 January 2024 with Hong Kong Trading and Settlement Holdings Limited its Monthly Securities Change Report for the year ended 31 December 2023. THE REPORT SHOWS THAT THE COMPANY DID NOT HAVE ANY CHANGES IN SHARES DURING THE REPORTING MONTH, INCLUDING ORDINARY SHARES, STOCK OPTIONS, WARRANTS, CONVERTIBLE STOCK NOTES AND OTHER RELATED AGREEMENTS OR ARRANGEMENTS. In addition, the Company confirms that all securities issued have been approved by the Board of Directors and comply with all the requirements of the Securities Listing Rules of the Hong Kong Stock Exchange Limited. The report was presented by the Joint Company Secretary Zhao Dongji.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more